Organization · Venture Capital
BEVC
BEVC is an early-stage venture capital firm based in Berkeley, California, focusing on investments at the intersection of life sciences, engineering, and computation. The firm targets transformational technology with high impact potential in health, energy, and materials.
Overview
What BEVC does
What BEVC is
BEVC is an early-stage venture capital firm based in Berkeley, California, focusing on investments at the intersection of life sciences, engineering, and computation. The firm targets transformational technology with high impact potential in health, energy, and materials.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find BEVC elsewhere
Open the official website or a supported primary organization account.
Capability profile
BEVC as a funder
Investment thesis
BEVC invests in transformational technology with high impact potential, focusing on the intersection of biology, health, AI, engineering, energy, and materials. The firm believes major companies can emerge from academic breakthroughs, shaped in startups and scaled through enterprise adoption.
Focus narrative
BEVC invests in transformational technology with high impact potential, primarily in the sectors of health, energy, and materials. The firm targets early-stage investments, specifically in Pre-Seed, Seed, and Series A stages, with a geographical focus on the San Francisco Bay Area.
Value beyond capital
BEVC provides capital along with hands-on technical, strategic, operational, and network support to its portfolio companies. The firm emphasizes close collaboration with founders to build defensible businesses.
Focus and fit
- Stages
- Pre-seed · Seed · Series A
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 8
Portfolio context
Addition Therapeutics: Develops RNA-only genetic medicines that can PRINT™ any genetic element at specific safe harbor sites. AIMATX: Utilizes AI-powered discovery and synthesis for breakthrough materials at unprecedented speed. Dextera Biosciences: Focuses on a new class of synthetic D-protein drugs to overcome the limitations of conventional antibody drugs. Insamo Therapeutics: Works on oral macrocyclic peptide drugs enabled by AI/ML and a trillion molecule display library. Khemia Metals: Aims to replace critical metals with earth-abundant alloys to create lighter, cheaper, and more sustainable batteries. Montara Therapeutics: Develops brain-selective therapies for neurological diseases. PinkDx: Engaged in non-invasive diagnostic development for women’s health conditions. Radar Therapeutics: Focuses on precision therapeutics built on smart mRNA logic.
Common questions
What to know about BEVC
Upseed classifies BEVC under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.